TuHURA Biosciences, Inc./NV
HURA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HURA
TuHURA Biosciences, Inc. is a pre-revenue immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapies, with a lead candidate IFx-Hu2.0 in Phase 3 trials and a cash position of $1.0M as of June 30, 2026.
Key risk: Cash runway risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$134.5M
Cash Runway
0.4 moLead Asset
tbs-2025 (Phase 1)
Next Catalyst
Phase3_Topline · Dec 30, 2032Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for TuHURA Biosciences, Inc./NV.
TuHURA Biosciences, Inc. is a pre-revenue immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapies, with a lead candidate IFx-Hu2.0 in Phase 3 trials and a cash position of $1.0M as of June 30, 2026.
- TuHURA is a pre-revenue immuno-oncology company focused on overcoming resistance to cancer immunotherapies [sec_mda · as of 2026-03-31].
- Lead product candidate IFx-Hu2.0 is in a Phase 3 trial as an adjunctive therapy [catalyst].
- Cash and equivalents were $1.0M as of June 30, 2026 [sec].
- Net loss was $9.2M for the three months ended June 30, 2026, and accumulated deficit reached $157.9M as of that date [sec_mda · as of 2026-08-14].
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-08-14].
What works
- TuHURA's strategy targets a large unmet need: overcoming primary and acquired resistance to checkpoint inhibitors, potentially broadening the impact of existing immunotherapies [sec_mda · as of 2026-03-31].
- The company has a diversified pipeline including IFx-2.0 and TBS-2025, which may reduce single-asset risk [sec_mda · as of 2026-08-14].
- A Phase 3 topline readout for IFx-Hu2.0 is expected by December 30, 2032, representing a potential value inflection point [catalyst].
What to weigh
- TuHURA has no approved products and no revenue from product sales, relying entirely on external financing [sec_mda · as of 2026-08-14].
- The company has a very limited cash runway of $1.0M as of June 30, 2026, which may not sustain operations without additional funding [sec].
- Significant operating losses continue, with a net loss of $9.2M in the most recent quarter and an accumulated deficit of $157.9M [sec_mda · as of 2026-08-14].
- Management acknowledges that capital may be depleted sooner than expected, and future funding is uncertain [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
TuHURA has no approved products and no product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 14, 2026
The company's strategy is to overcome resistance to cancer immunotherapies.
“overcome acquired resistance to cancer immunotherapies related to the immune suppressing characteristics of the tumor microenvironment.”
SEC MD&A · March 31, 2026
TuHURA has incurred significant operating losses and has a large accumulated deficit.
“We are not profitable and have incurred significant operating losses in each period since our inception, including net losses of $9.2 million and $16.8 million for the three and six months ended June 30, 2026, and $30.1 million for the year ended December 31, 2025. As of June 30, 2026, we had an accumulated deficit of $157.9 million.”
SEC MD&A · August 14, 2026
Management warns that cash may be depleted sooner than expected.
“we may deplete our available capital resources sooner than management expects.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2032-12-30 · Phase3_Topline · ifx-hu2 — Topline results from a randomized, double-blind, placebo-controlled Phase 3 trial of IFx-Hu2.0 as an adjunctive therapy.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Only $1.0M cash as of June 30, 2026, insufficient to fund operations without near-term financing [sec].
- Clinical trial risk — Phase 3 trial of IFx-Hu2.0 may fail to meet endpoints, delaying or preventing approval [catalyst].
- Financing risk — Company may be unable to raise additional funds on favorable terms or at all [sec_mda · as of 2026-05-15].
- No revenue history — No approved products and no product revenue, entirely dependent on external capital [sec_mda · as of 2026-08-14].
What to watch
- Phase 3 topline data for IFx-Hu2.0, expected by December 30, 2032 [catalyst].
- Ability to secure additional financing given the $1.0M cash position as of June 30, 2026 [sec].
- Progress of preclinical/clinical programs for TBS-2025 and other pipeline candidates [sec_mda · as of 2026-08-14].
- Any updates on regulatory interactions or partnership deals that could extend cash runway [sec_mda · as of 2026-05-15].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run TuHURA Biosciences, Inc./NV through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TuHURA Biosciences, Inc./NV facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
0.4 months
D/E 0.72 · 0% dilution
Lead: Phase 1
1 candidate
1 upcoming, next in ~2314d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
87
Total value held
$20.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,148,456 | $7.4M |
| blackrock, inc. | 2,450,256 | $4.4M |
| geode capital management, llc | 986,922 | $1.8M |
| aqr capital management llc | 607,168 | $1.1M |
| state street corp | 512,913 | $918K |
| northern trust corp | 298,187 | $534K |
| vanguard fiduciary trust co | 287,133 | $514K |
| vanguard portfolio management llc | 253,641 | $454K |
| bank of new york mellon corp | 211,568 | $379K |
| cetera investment advisers | 140,244 | $251K |
Showing top 10 of 87 institutional holders of TuHURA Biosciences, Inc./NV. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 16.8%
- Days to cover
- 6.3
- Shares short
- 8,260,038
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HURA short interestGovernance
Frequently asked questions
What is the AI investment thesis for TuHURA Biosciences, Inc./NV?
TuHURA Biosciences, Inc. is a pre-revenue immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapies, with a lead candidate IFx-Hu2.0 in Phase 3 trials and a cash position of $1.0M as of June 30, 2026.
What is TuHURA Biosciences, Inc./NV's lead drug candidate?
TuHURA Biosciences, Inc./NV's most advanced tracked candidate is tbs-2025 (Phase 1) for Solid tumors.
What is TuHURA Biosciences, Inc./NV's next catalyst?
TuHURA Biosciences, Inc./NV's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther" — expected December 30, 2032.
Who is the CEO of TuHURA Biosciences, Inc./NV?
Dr. James A. Bianco M.D. is the chief executive officer of TuHURA Biosciences, Inc./NV (HURA).
Where is TuHURA Biosciences, Inc./NV headquartered?
TuHURA Biosciences, Inc./NV (HURA) is headquartered in Tampa, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.